The Prostate Cancer Blog for Wives and Partners lets you know when new information has been added to our site. Anytime a new page is created — or we feel there is something worth noting — it will be posted here.
While not surprising, patient-physician communication is critical for the health of prostate cancer survivors who have had their prostates surgically removed, according to a new study (Ernstmann et al) published in BJU International. At least 3 years after prostatectomy, patient-physician communication was associated with helping men cope with their disease and for improving their health-related quality of life. The authors of the study, which involved 1,772 men, suggest that a “trustful relationship” should be part of long-term follow-up care for prostate cancer patients and survivors. May 16, 2016.
A new and novel test can detect malignancies and differentiate between high-grade and low-grade prostate cancer, according to an interim analysis of a six-center clinical trial of 132 patients, as reported by the Cleveland Clinic at the American Urological Association annual meeting. The new test identifies molecular changes in the prostate specific antigen (PSA) protein. We all know that current PSA testing is not ideal, but it’s the only game in town. This IsoPSA test identifies prostate cancer differently and demonstrated improved diagnostic accuracy in early clinical trial results. We look forward to seeing the complete findings of the clinical trial when they are released. May 13, 2016.
We already know that men may experience a rise in PSA after sexual activity (it is suggested to avoid sex a few days prior to testing). Now men who are sexually active following radiation treatment for prostate cancer may experience a small rise and fall in PSA level, according to a new study by Japanese researchers (Matsushima et al) that was published in the International Journal of Urology. These “bounces,” which may go on for years, have only been noted in men who have had radiation therapy. Younger men appear to have a greater risk of experiencing them. In the study, researchers looked at data from 154 men who had been treated with brachytherapy for localized prostate cancer and were followed for a minimum of 24 months. Thirty-eight men (24.7%) experienced PSA bounce. May 4, 2016.
We’ve always known that depression is a potential negative side effect with androgen deprivation therapy (ADT) for prostate cancer. Now a study (Dinh et al) published in the Journal of Clinical Oncology has determined that men are at a “significantly increased risk” of developing depression with ADT and that risk increases with the length of therapy. Researchers reviewed a database of about 79,000 men older than age 65 (from 1992 to 2006) who had stage I to stage III prostate cancer. Overall, men who had ADT had a 23% increased risk of depression. Researchers also found that the longer a man had ADT, the greater his risk of developing depression. Twelve percent of men developed depression from with ≤ 6 months of ADT treatment; 26% of men developed depression with 7 to 11 months of ADT treatment, and 37% of men developed depression with ≥ 12 months of ADT treatment. May 2, 2016.
Another study is touting the benefits of moderate to high-level physical activity to help improve a man's chance of surviving prostate cancer. A reduced risk of prostate cancer specific mortality (death) has already been associated with vigorous physical activity, both before and after a man is diagnosed, according to research by Wang et al, which was presented at the American Association for Cancer Research Annual Meeting this week. Now, researchers say that “sitting time” (watching television, reading, sitting or driving in a car, etc.) is not associated with a reduced risk of prostate cancer specific mortality. The researchers looked at data from more than 10,000 men (ages 50 to 93) who did not have metastatic prostate cancer. Men who exercised the most had a 35 percent lower risk of dying from prostate cancer than men who exercised the least. April 19, 2016.
One of the challenges of active surveillance (sometimes called watchful waiting) is that there is no way to predict if — or when — cancer may spread. Now researchers are telling us that more than three percent of men who are on active surveillance had prostate cancer metastasis, according to a new study (Yamamoto et al) published in the The Journal of Urology. In this single center, prospective cohort study, 30 of 980 men experienced prostate cancer metastasis. The median age of men was 70 years, median PSA was 6.2 ng/ml, and median time to metastasis was 8.9 years. Median follow up was 6.3 years. The study authors conclude that active surveillance may be safe in men at low risk and certain patients at intermediate risk (Gleason score 6 and PSA > 10 ng/ml). April 16, 2016
Men with low-risk prostate cancer who receive a slightly higher dose of radiation for 5.6 weeks may be able to control their prostate cancer as well as men who receive standard radiation for 8 weeks, according to a new study (Lee at al) published in the Journal of Clinical Oncology. At five years, overall survival and disease-free survival were the same between both groups. April 13, 2016.
Using animal (mouse) models, researchers have discovered that many types of androgen deprivation therapy may suppress a man’s adaptive immune responses — which could prevent immunotherapies from being effective — if both treatments are not timed properly. These findings come from a study (Yang et al) that was published in Science Translational Medicine. More studies are needed, but this is definitely something to discuss with your doctor if you will be receiving both types of therapies. April 8, 2016.
Men who received radiation treatment for prostate cancer from centers that frequently perform radiation therapy had a better overall survival rate, according to a new study (Chen et al) published in the International Journal of Radiation Oncology, Biology, and Physics. When researchers analyzed data from more than 19,500 men with prostate cancer who were treated with radiation at 1,099 facilities, they found a small difference in the 7-year overall survival of men who were treated at a facility in the top 20 percent for radiation volume (76% vs 74%) compared to men treated at centers in the bottom 80% percent for radiation volume. A center that treated over 43 men per year was considered to be in the top 20 percent for radiation volume. March 28, 2016.
Men who have prostate cancer that spreads only to the lymph nodes may survive longer than men who have disease that has spread to other areas, according to a new study (Halabi et al) published in the Journal of Clinical Oncology. When researchers analyzed data from 8,820 men with prostate cancer they found that men with liver metastases had the lowest median overall survival (MOS) of 13.5 months. Men with lung metastases had MOS of 19.4 months. Men with nonvisceral bone metastases had MOS of 21.3 months and men with lymph node only metastases had MOS of 31.6 months. March 14, 2016.
Men with low vitamin D levels were more likely to have fast growing prostate cancer tumors than men with normal levels, according to a new study (Nyame et al), which was published in the Journal of Clinical Oncology. In this study of 190 men who had their prostate glands removed via surgery, close to 46 percent of men had more aggressive prostate cancer. A significant number of those men also had low vitamin D (called serum 25-OH D) levels before they had surgery. If these findings can be confirmed by a much larger study, serum 25-OH D levels may be a useful biomarker to predict aggressiveness of the disease. March 3, 2016.
Researchers have found a way to tell the difference between malignant and benign prostate tissue with a reported 85 percent sensitivity, 86 percent specificity, and 86 percent accuracy, according to a small study that was recently published in the Journal of Urology. Researchers at UT Southwestern Medical Center used a tool called light reflectance spectroscopy (LRS) to analyze 17 prostate gland specimens after they were removed during surgery. LRS measures light intensity that is reflected or backscattered from tissues. While further studies are needed, LRS may one day help surgeons determine in real time how much tissue surrounding the prostate gland needs to be removed (called surgical margins). February 29, 2016.
Male pattern baldness has long been associated with an increased risk of prostate cancer in observational studies (studies that draw influences from a sample to a population but the independent variable is not under the control of the researcher). Now results of a prospective study that followed men over time (called the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study or NHEFS) suggest that bald men have a 1.5 times greater risk of death due to prostate cancer. Researchers looked at data from 4,316 men in the study (called a cohort) who had no previous cancer diagnosis at baseline and were 25 to 74 years old. Of that number, 107 men died from prostate cancer. Before baldness can be considered a conclusive risk factor for prostate cancer, the study results should be replicated. February 20, 2016.
Researchers working at the University of Copenhagen have discovered a new prognostic biomarker that is very specific to prostate cancer cells (a neuropeptide called pro-NPY), which may help predict a man’s risk of dying from the disease. It may also help doctors determine if a man should have surgery (radical prostatectomy) when he is first diagnosed with prostate cancer, or whether surgery can safely be delayed. February 16, 2016.
Prostate cancer survivors are being invited to share their experiences in a web-based Prostate Cancer Registry that was developed by the Center for Cancer Research and Therapeutic Development at Clark Atlanta University in partnership with the Georgia Prostate Cancer Coalition. The registry is designed to gather information about men’s experiences and needs, which will be used to fuel research. It will also monitor trends and changes in the epidemiological, emotional, and health status of prostate cancer survivors. February 9, 2016.
Always consult a medical professional.